Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Current Deferred Revenue (2016 - 2021)

Historic Current Deferred Revenue for Arcadia Biosciences (RKDA) over the last 8 years, with Q2 2021 value amounting to $63000.0.

  • Arcadia Biosciences' Current Deferred Revenue changed N/A to $63000.0 in Q2 2021 from the same period last year, while for Jun 2021 it was $63000.0, marking a year-over-year change of. This contributed to the annual value of $8000.0 for FY2020, which is 8095.24% down from last year.
  • Per Arcadia Biosciences' latest filing, its Current Deferred Revenue stood at $63000.0 for Q2 2021.
  • In the past 5 years, Arcadia Biosciences' Current Deferred Revenue ranged from a high of $1.0 million in Q4 2017 and a low of $8000.0 during Q4 2020
  • Moreover, its 5-year median value for Current Deferred Revenue was $88000.0 (2018), whereas its average is $310875.0.
  • In the last 5 years, Arcadia Biosciences' Current Deferred Revenue plummeted by 9680.85% in 2019 and then surged by 27058.82% in 2021.
  • Quarter analysis of 5 years shows Arcadia Biosciences' Current Deferred Revenue stood at $1.0 million in 2017, then tumbled by 90.4% to $96000.0 in 2018, then plummeted by 56.25% to $42000.0 in 2019, then plummeted by 80.95% to $8000.0 in 2020, then skyrocketed by 687.5% to $63000.0 in 2021.
  • Its Current Deferred Revenue was $63000.0 in Q2 2021, compared to $63000.0 in Q1 2021 and $8000.0 in Q4 2020.